We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 27,233

Court finds Dow claims clearly indefinite
  • Foley & Lardner LLP
  • USA
  • September 3 2015

In Dow Chemical Co. v. Nova Chemicals Corp., the Federal Circuit held claims reciting a limitation that could be calculated in several ways


High Court states the obvious: AstraZeneca AB v Apotex Pty Ltd appeal decided
  • King & Wood Mallesons
  • Australia
  • September 3 2015

In a widely anticipated decision, the High Court has upheld a decision of the Full Federal Court (which was made by five, rather than the usual three


AstraZeneca appeal dismissed
  • AJ Park
  • Australia
  • September 3 2015

Last year, the Full Federal Court of Australia ruled that AstraZeneca's patent relating to Crestor (a cholesterol-lowering drug) was invalid due to


Kimble v. Marvel: a cautionary tale for post-expiration royalties
  • Baker Botts LLP
  • USA
  • September 3 2015

The Supreme Court carefully guards the twenty-year expiration date of a patent, allowing the public the unrestricted right to make or use a patented


Three strikes, you’re out: Rosuvastatin generics in the clear
  • Shelston IP
  • Australia
  • September 3 2015

The High Court has unanimously sided with the Full Court, finding that there was no error in its reasoning in applying the test for inventive step


Filing reissuesremoving the cloud of uncertainty caused by Alice
  • Baker Botts LLP
  • USA
  • September 3 2015

In its 2014 Alice Corporation v. CLS Bank International decision, the Supreme Court invalidated a patent directed to managing settlement risk because


High Court upholds earlier decision that AstraZeneca's cholesterol-lowering patent is obvious
  • Clayton Utz
  • Australia
  • September 3 2015

In a closely-watched patent decision, the High Court has unanimously dismissed AstraZeneca's appeal concerning its low-dose patent for the


Arbitrator removed after repeated appointment in patent enforcement disputes
  • BMA
  • Portugal
  • September 3 2015

Law 622011 which established a mandatory arbitration system for the resolution of disputes concerning industrial property rights relating to


High Court dismisses AstraZeneca appeal
  • Spruson & Ferguson
  • Australia
  • September 2 2015

In our recent article of 26 June 2015 we reported on the High Court of Australia hearing on 13 and 14 May 2015 of the Appeal in the rosuvastatin case


Compulsory licences now available for export of patented pharmaceuticals
  • Shelston IP
  • Australia
  • September 2 2015

BackgroundAustralia is a signatory to the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (the